6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-13), Ensysce Biosciences's 6-1 Month Momentum % is -51.48%.
The industry rank for Ensysce Biosciences's 6-1 Month Momentum % or its related term are showing as below:
ENSC's 6-1 Month Momentum % is ranked worse than 89.2% of 1518
companies
in the Biotechnology industry
Industry Median: -4.43
vs ENSC: -51.48
Competitive Comparison of Ensysce Biosciences's 6-1 Month Momentum %
For the Biotechnology subindustry, Ensysce Biosciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ensysce Biosciences 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Ensysce Biosciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ensysce Biosciences (Ensysce Biosciences) Business Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the?Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENSC has been successfully added to your